CJC-1295 is a tetrasubstituted form of human growth hormone-releasing factor (1-29) with an added maleimidopropionamide derivative of lysine at its C-terminus, designed to bind serum albumin after injection and so extend its plasma half-life.
emerging — human data exists, and it is thin or contested
every claim resolves to its source
All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.
emerging
Claim: Randomized, placebo-controlled ascending-dose trials in healthy adultsstanding
resolved
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA
Claim: hGRF(1-29)-albumin bioconjugates; identification of CJC-1295standing
resolved
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.
Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP
A claim's standing is its latest row in an append-only history; a tombstone names the later evidence and the reason. The Graveyard and the Resurrection Yard.
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.